Creating a therapeutic revolution: Practitioners lead the way

Much of the contemporary debate in mental health innovation centers on treatment—mechanisms of action, clinical endpoints, and regulatory frameworks. Yet effective care depends not only on interventions, but also on the relationships and organizational structures that enable them. One of the most developed structures of medicine that addresses this aspect is the therapeutic alliance.

Alliance Clinical Foundations

The therapeutic alliance has been developed in psychotherapy as a framework that describes the collaborative relationship between the clinician and the patient. Decades of empirical research have shown that alliance quality is related to treatment adherence, engagement, and outcomes in psychiatric conditions.

The American Medical Association formalized this concept in its Code of Medical Ethics, defining the patient-physician relationship as a “collaborative effort” based on a “mutually respectful alliance,” and asserting that “the practice of medicine is fundamentally an ethical activity.”

Traditionally, this association has been examined within the confines of the clinic. But the principle that underlies it—collaboration built in the service of patient outcomes—has implications that extend beyond the dyadic clinical event.

A system-wide mental health challenge

Post-traumatic stress disorder (PTSD), major depressive disorder, substance use disorders, and traumatic brain injury remain among the most complex and high-burden psychiatric conditions. Remission rates remain suboptimal in treatment-resistant populations, and relapse is common.

For US veterans, the urgency is especially acute.

Department of Veterinary Affairs National Veterans Suicide Prevention Annual Report Clearly states: “Reducing veteran suicide is the Department of Veterans Affairs’ (VA’s) highest clinical priority.” Veterans experience higher rates of PTSD, alcohol use disorder, and depression than the general population. Peer-reviewed data published American Journal of Managed Care It indicates that nearly one in three veterans has been diagnosed with at least one mental health disorder, and 41 percent receive a diagnosis related to mental health or behavioral adjustment.

These epidemiological realities highlight the need not only for treatment innovation, but also for a coordinated institutional response.

Bilateral support for expanding clinical research

In this context, bipartisan legislation in the US Congress has focused on expanding structured research on emerging therapies for veterans, including psychoactive therapies currently under investigation in FDA-regulated trials.

The bipartisan leadership of the Congressional PATH (Advancing Treatment of Psychedelics) Caucus has been instrumental in the expansion of psychotherapy. Their legislative efforts are aimed at expanding VA participation in controlled clinical trials, establishing investigative research programs, expanding access pathways where appropriate, and developing VA centers of excellence dedicated to evaluating innovative psychotherapies.

These recommendations do not change the FDA’s standards of evidence. Instead, they seek to build organizational capacity to conduct rigorous research within established regulatory frameworks. The importance is less in political symbolism than in structural alignment: federal agencies, research institutions, and health care systems coordinate to provide high-quality evidence.

Institutional engagement within VA

The Veterans Health Administration is the largest integrated health system in the United States, serving nearly 9 million patients at more than 170 medical centers and more than 1,000 outpatient locations. Its scale and centralized architecture make it uniquely positioned to track multi-site clinical trials and long-term outcomes in a single system.

Veterans Affairs Secretary Doug Collins has publicly acknowledged the severity of the crisis, saying that “veteran suicide has long been a scourge in our nation.” In a remarkable public moment, he became the first member of an administration to speak from the White House about the potential of psychiatric drugs, signaling openness to evaluating the emerging treatment within a research-based framework.

The VA is currently collaborating on several psychiatric drug trials, including studies conducted at VA health centers. Like other investigational psychotherapies, these studies proceed through phased clinical development designed to evaluate safety, dosage, efficacy, durability and risk.

Scientific standards remain constant. What has grown is the level of institutional involvement.

A broad roadmap for mental health innovation

Melissa Lavasani, executive director of the nonprofit Psychedelic Medicine Coalition, described the moment as “a mind-shift in the future of mental health in America.” She noted that the Veterans Health Administration—serving 9 million patients with a workforce of nearly 400,000 in hundreds of facilities—represents more than the policy environment. According to her, the current effort is “more than policy recommendations—it’s a blueprint for a new era of mental health care in the United States.”

Her observation reflects a widely applicable science principle: large integrated systems often act as translational accelerators. When research infrastructure, regulatory clarity, and health care delivery work in alignment, innovation can move more efficiently from controlled trials to real-world care settings.

From Dyadic Alliance to Institutional Alliance

The therapeutic alliance literature consistently shows that alignment between clinician and patient improves measurable outcomes. At the systems level, similarities between agencies may affect how effectively new treatments are evaluated and, if approved, implemented.

In translational psychosis, fragmentation can slow progression. Research findings may not be integrated into models of care. Funding uncertainty can confound long-term study design. Political polarization can prevent sustainable cooperation.

When policymakers collaborate across partisan lines to support the production of structured evidence, the result is more than just legislative movement. This is a predictable increase in funding, clear research pathways, and robust infrastructure for clinical investigations.

In this sense, the extension of the therapeutic alliance beyond the therapy room is not metaphorical. It is operational.

Mental health innovation will ultimately be judged by data—safety profiles, effect sizes, persistence of response, and effectiveness in the real world. Emergency treatments, including psychedelic-assisted treatments, must meet established scientific criteria before widespread use.

But generating this information depends on coordinated institutional engagement.

The original therapeutic alliance described a shared commitment between the clinician and the patient. Applied more broadly, the same principles suggest that continued progress in mental health requires alignment among researchers, regulators, policymakers, and health care systems.

For veterans with suicidal and complex mental illnesses, such adjustments may prove as necessary as any therapeutic advancement.